AbbVie Inc.

ABBV 10-K · FY 2025
API behind this page

ABBV FY 2025 request

Playground key active
Request URL /api/financials?ticker=ABBV&year=2025&quarter=4&full_year_mode=true
waiting 0 ms 
Pick an endpoint and run the request.
curl

Income Statement

JSON CSV Excel
Income Statement
Metric FY 2025 FY 2024 YoY
Revenue 61,160 56,334 +8.6%
Cost of Revenue 18,204 16,904 +7.7%
Show Equity Components breakouts
Accumulated Gain Loss Cash Flow Hedge Including Noncontrolling Interest · Foreign Exchange Forward -66 -73 +9.6%
Selling, General & Administrative 14,010 14,752 -5.0%
Research And Development Expense Excluding Acquired In Process Cost 9,096 12,791 -28.9%
Research And Development Asset Acquired Other Than Through Business Combination Written Off 5,016 2,757 +81.9%
Show Counterparty Name breakouts
Other individually insignificant arrangements · Collaborative Arrangement 602 975 -38.3%
Show Type Of Arrangement breakouts
Collaborative Arrangement 4,808 2,627 +83.0%
Other Operating Income Expense Net -241 -7 -3342.9%
Total Costs & Expenses 46,085 47,197 -2.4%
Operating Income 15,075 9,137 +65.0%
Interest Income Expense Nonoperating Net 2,627 2,160 +21.6%
Show Equity Components breakouts
Accumulated Gain Loss Cash Flow Hedge Including Noncontrolling Interest · Treasury Lock 21 23 -8.7%
Aoci Derivative Qualifying As Hedge Excluded Component Parent · Net Investment Hedging -145 -123 -17.9%
Foreign Currency Transaction Gain Loss Before Tax 58 21 +176.2%
Other Non-Operating Income (Expense) 5,793 3,240 +78.8%
Income Before Taxes 6,597 3,716 +77.5%
Income Tax Expense (Benefit) 2,364 -570 +514.7%
Show Equity Components breakouts
Accumulated Gain Loss Cash Flow Hedge Including Noncontrolling Interest · Reclassification Out Of Accumulated Other Comprehensive Income 20 21 -4.8%
Aoci Derivative Qualifying As Hedge Excluded Component Parent · Net Investment Hedging 31 27 +14.8%
Net Income 4,233 4,286 -1.2%
Net Income Loss Attributable To Noncontrolling Interest 7 8 -12.5%
Net Income 4,226 4,278 -1.2%
Show Equity Components breakouts
Accumulated Gain Loss Cash Flow Hedge Including Noncontrolling Interest · Reclassification Out Of Accumulated Other Comprehensive Income 67 75 -10.7%
Aoci Derivative Qualifying As Hedge Excluded Component Parent · Net Investment Hedging 114 96 +18.8%
Retained Earnings 4,226 4,278 -1.2%
EPS (Basic) 2.37 2.4 -1.2%
EPS (Diluted) 2.36 2.39 -1.3%
Wtd Avg Shares (Basic) 1,769 1,769 0.0%
Wtd Avg Shares (Diluted) 1,773 1,773 0.0%
Revenue 61,160 56,334 +8.6%
Show Product Lines breakouts
All other 2,627 3,032 -13.4%
Alphagan/Combigan · Eye Care 197 248 -20.6%
Alphagan/Combigan · Non Us 144 153 -5.9%
Alphagan/Combigan · US 53 95 -44.2%
Botox Cosmetic · Aesthetics 2,602 2,720 -4.3%
Botox Cosmetic · Non Us 1,098 1,038 +5.8%
Botox Cosmetic · US 1,504 1,682 -10.6%
Botox Therapeutic · Neuroscience 3,769 3,283 +14.8%
Botox Therapeutic · Non Us 618 565 +9.4%
Botox Therapeutic · US 3,151 2,718 +15.9%
Creon · US 1,512 1,383 +9.3%
Duodopa · Neuroscience 381 447 -14.8%
Duodopa · Non Us 308 351 -12.3%
Duodopa · US 73 96 -24.0%
Elahere · Non Us 83 2 +4050.0%
Elahere · Oncology 690 479 +44.1%
Elahere · US 607 477 +27.3%
Epkinly · Non Us 90 28 +221.4%
Epkinly · Oncology 271 146 +85.6%
Humira · Immunology 4,540 8,993 -49.5%
Humira · Non Us 1,478 1,851 -20.2%
Humira · US 3,062 7,142 -57.1%
Imbruvica · Oncology 2,869 3,347 -14.3%
Imbruvica · US 2,048 2,448 -16.3%
Juvederm Collection · Aesthetics 993 1,177 -15.6%
Juvederm Collection · Non Us 608 708 -14.1%
Juvederm Collection · US 385 469 -17.9%
Linzess/Constella · Non Us 43 38 +13.2%
Linzess/Constella · Other Key Products 907 954 -4.9%
Linzess/Constella · US 864 916 -5.7%
Lumigan/Ganfort · Eye Care 410 429 -4.4%
Lumigan/Ganfort · Non Us 221 242 -8.7%
Lumigan/Ganfort · US 189 187 +1.1%
Mavyret · Non Us 682 716 -4.7%
Mavyret · Other Key Products 1,317 1,311 +0.5%
Mavyret · US 635 595 +6.7%
Other Aesthetics · Aesthetics 1,265 1,279 -1.1%
Other Aesthetics · Non Us 164 161 +1.9%
Other Aesthetics · US 1,101 1,118 -1.5%
Other Eye Care · Eye Care 1,009 1,071 -5.8%
Other Eye Care · Non Us 421 427 -1.4%
Other Eye Care · US 588 644 -8.7%
Other Neuroscience · Neuroscience 207 239 -13.4%
Other Neuroscience · Non Us 15 16 -6.2%
Other Neuroscience · US 192 223 -13.9%
Other Oncology · US 33 — —
Ozurdex · Eye Care 493 494 -0.2%
Ozurdex · Non Us 369 356 +3.7%
Ozurdex · US 124 138 -10.1%
Qulipta · Neuroscience 1,036 658 +57.4%
Qulipta · Non Us 130 30 +333.3%
Qulipta · US 906 628 +44.3%
Rinvoq · Immunology 8,304 5,971 +39.1%
Rinvoq · Non Us 2,364 1,712 +38.1%
Rinvoq · US 5,940 4,259 +39.5%
Skyrizi · Immunology 17,562 11,718 +49.9%
Skyrizi · Non Us 2,360 1,632 +44.6%
Skyrizi · US 15,202 10,086 +50.7%
Ubrelvy · Neuroscience 1,271 1,006 +26.3%
Ubrelvy · Non Us 32 25 +28.0%
Ubrelvy · US 1,239 981 +26.3%
Venclexta · Non Us 1,486 1,349 +10.2%
Venclexta · Oncology 2,792 2,583 +8.1%
Venclexta · US 1,306 1,234 +5.8%
Vraylar · Neuroscience 3,621 3,267 +10.8%
Vraylar · Non Us 9 7 +28.6%
Vraylar · US 3,612 3,260 +10.8%
Vyalev · Neuroscience 482 99 +386.9%
Vyalev · Non Us 315 98 +221.4%
Vyalev · US 167 1 +16600.0%
Show Geography breakouts
All other countries 5,759 5,449 +5.7%
AU 459 463 -0.9%
BR 478 464 +3.0%
CA 1,222 1,088 +12.3%
CN 1,006 917 +9.7%
DE 1,738 1,465 +18.6%
ES 609 528 +15.3%
FR 806 776 +3.9%
GB 626 522 +19.9%
IT 580 511 +13.5%
JP 1,274 1,122 +13.5%
US 46,603 43,029 +8.3%
Comprehensive Income 5,007 4,658 +7.5%
Net Income Loss Available To Common Stockholders Basic 4,186 4,238 -1.2%
Interest Expense 2,893 2,808 +3.0%

Balance Sheet

Balance Sheet
Metric FY 2025 FY 2024 YoY
Current Assets
Cash & Cash Equivalents 5,229 5,524 -5.3%
Short-Term Investments 28 31 -9.7%
Accounts Receivable 12,589 10,919 +15.3%
Show Counterparty Name breakouts
Janssen Biotech, Inc · Collaborative Arrangement 218 237 -8.0%
Inventory 4,951 4,181 +18.4%
Prepaid Expense And Other Assets 6,265 4,927 +27.2%
Total Current Assets 29,062 25,582 +13.6%
Non-Current Assets
Long Term Investments 268 279 -3.9%
Property, Plant & Equipment 5,628 5,134 +9.6%
Goodwill 35,640 34,956 +2.0%
Other Non-Current Assets 10,721 9,142 +17.3%
Total Assets 133,960 135,161 -0.9%
Operating Lease Right-of-Use Assets 737 723 +1.9%
Intangible Assets 47,360 54,866 -13.7%
Show Finite Lived Intangible Assets By Major Class breakouts
Developed Technology Rights 46,390 53,175 -12.8%
Licensing Agreements 970 1,691 -42.6%
Other Assets
Intangible Assets Net Excluding Goodwill 52,641 60,068 -12.4%
Current Liabilities
Short Term Borrowings 2,499 — —
Show Short Term Debt Type breakouts
364 day Term Loan Credit Agreement 2 — —
Commercial Paper 499 — —
Long Term Debt And Capital Lease Obligations Current 6,056 6,804 -11.0%
Accounts Payable And Accrued Liabilities Current 34,734 31,945 +8.7%
Show Counterparty Name breakouts
Janssen Biotech, Inc · Collaborative Arrangement 189 282 -33.0%
Total Current Liabilities 43,289 38,749 +11.7%
Accounts Payable 3,592 2,945 +22.0%
Non-Current Liabilities
Deferred Tax Liabilities 2,389 2,579 -7.4%
Other Non-Current Liabilities 32,569 30,129 +8.1%
Long-Term Debt 64,503 — —
Operating Lease Liabilities 689 697 -1.1%
Accrued Income Taxes Noncurrent 364 1,261 -71.1%
Other Liabilities
Long Term Debt And Capital Lease Obligations 58,941 60,340 -2.3%
Minority Interest 42 39 +7.7%
Stockholders' Equity
Common Stock Value Outstanding 18 18 0.0%
Treasury Stock Value -9,146 -8,201 -11.5%
Additional Paid In Capital Common Stock 22,495 21,333 +5.4%
Retained Earnings -15,493 -7,900 -96.1%
Accumulated Other Comprehensive Income -1,144 -1,925 +40.6%
Total Stockholders' Equity -3,270 3,325 -198.3%
Stockholders Equity Including Portion Attributable To Noncontrolling Interest -3,228 3,364 -196.0%
Show Equity Components breakouts
Accumulated Defined Benefit Plans Adjustment Including Portion Attributable To Noncontrolling Interest -243 -664 +63.4%
Accumulated Foreign Currency Adjustment Including Portion Attributable To Noncontrolling Interest -633 -2,114 +70.1%
Accumulated Gain Loss Cash Flow Hedge Including Noncontrolling Interest 154 304 -49.3%
Accumulated Other Comprehensive Income -1,144 -1,925 +40.6%
Additional Paid In Capital 22,495 21,333 +5.4%
Aoci Including Portion Attributable To Noncontrolling Interest -1,144 -1,925 +40.6%
Common Stock 18 18 0.0%
Net investment hedging activities -422 549 -176.9%
Noncontrolling Interest 42 39 +7.7%
Retained Earnings -15,493 -7,900 -96.1%
Treasury Stock Common -9,146 -8,201 -11.5%
Total Liabilities & Equity 133,960 135,161 -0.9%

Cash Flow Statement

Cash Flow Statement
Metric FY 2025 FY 2024 YoY
Operating Activities
Depreciation 762 764 -0.3%
Amortization Of Intangible Assets 7,377 7,622 -3.2%
Deferred Income Taxes -492 -1,449 +66.0%
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 6,495 3,771 +72.2%
Payment For Contingent Consideration Liability Operating Activities -2,865 -1,995 -43.6%
Stock-Based Compensation 955 911 +4.8%
Upfront Costs Related To Collaborations 5,016 2,757 +81.9%
Non Cash Litigation Reserve Adjustments Net Of Cash Payments -933 508 -283.7%
Impairment Of Intangible Assets Excluding Goodwill 847 4,476 -81.1%
Other Non-Cash Items -3 -63 +95.2%
Change in Accounts Receivable -1,490 207 -819.8%
Change in Inventory -234 -319 +26.6%
Change in Prepaid & Other Assets -827 361 -329.1%
Increase Decrease In Accounts Payable And Accrued Liabilities 951 177 +437.3%
Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable -762 -3,208 +76.2%
Net Cash from Operations 19,030 18,806 +1.2%
Investing Activities
Payments To Acquire Businesses Net Of Cash Acquired -204 -17,493 +98.8%
Payments To Acquire Other Investments -5,237 -3,024 -73.2%
Capital Expenditures -1,214 -974 -24.6%
Payments To Acquire Marketable Securities -35 -73 +52.1%
Proceeds From Sale Maturity And Collections Of Investments 76 555 -86.3%
Other Investing Activities -29 189 -115.3%
Net Cash from Investing -6,643 -20,820 +68.1%
Financing Activities
Proceeds From Repayments Of Commercial Paper 499 — —
Proceeds From Short Term Debt 4,798 5,008 -4.2%
Repayments Of Other Short Term Debt -2,798 -5,008 +44.1%
Proceeds From Issuance Of Long Term Debt 3,994 16,963 -76.5%
Repayments Of Long Term Debt And Capital Securities -6,797 -9,613 +29.3%
Payment Of Financing And Stock Issuance Costs -23 -99 +76.8%
Payments Of Dividends -11,657 -11,025 -5.7%
Share Repurchases -980 -1,708 +42.6%
Proceeds From Stock Options Exercised 172 214 -19.6%
Proceeds From Payments For Other Financing Activities 68 57 +19.3%
Net Cash from Financing -12,724 -5,211 -144.2%
Supplemental
Interest Paid 3,002 2,811 +6.8%
Income Taxes Paid 3,626 4.1 +88339.0%
Other Cash Flow
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 42 -65 +164.6%
Net Change in Cash -295 -7,290 +96.0%
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 5,229 5,524 -5.3%

Values in millions USD. Source: SEC EDGAR 10-K filing.

This table is rendered from the same JSON returned by /api/financials.

Get API Key